An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome

Study Description

To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in participants ages 4 to \<18 years, in the treatment of 22q.11.2 Deletion syndrome (22qDS).

Study Details

Registry ID:

NCT05149898

Conditions:

22Q11.2 Deletion Syndrome

Phase:

Phase 2

Target Enrollment:

20 participants

Start Date:

February 19, 2020

Age Range:

4–17 years

Healthy Volunteers:

No

Study Locations (3 sites)

• Greenwood Genetic Center
  Greenville, South CarolinaUnited States, United States
• Genetics Clinics Australia
  Melbourne, VictoriaAustralia, Australia
• Lady Cilento Children's Hospital - South Brisbane
  Brisbane, QueenslandAustralia, Australia

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →